New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
06:54 EDTLH, MYGNMyriad remains in Horizon New Jersey network, says William Blair
William Blair believes there is confusion around Horizon BCBS of New Jersey's BRCA commentary, which it feels attributed to the recent pullback in shares of Myriad Genetics (MYGN). The firm said Horizon reiterated LabCorp's (LH) preferred network status and suggested that doctors should use LabCorp for BRCA testing. The insurer does not refer to a change in Myriadís network status as a participating provider in Horizonís network, the firm points out. William Blair says it has not seen evidence that Myriad is being excluded as a network provider. It maintains an Outperform rating on the stock.
News For MYGN;LH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
07:22 EDTLHDespite rumor, Quest takeover seems unlikely, says Wells Fargo
Subscribe for More Information
May 22, 2015
12:34 EDTLHOn The Fly: Top stock stories at midday
Subscribe for More Information
12:10 EDTLHQuest declines comment to Bloomberg on takeover speculation
Quest Diagnostics (DGX) declined comment to Bloomberg regarding the takeover speculation that pushed the company's stock higher today. Shares of Quest are up $7.01 to $80.89 in midday trading. Shares spiked earlier in the trading day amid talk among traders that Quest hired an investment bank to explore a sale after being approached by a suitor. The talk is unconfirmed speculation that has not been reported by any news agencies. Quest peer LabCorp (LH) is up $1.74 to $122.10 at midday.
10:46 EDTLHLabCorp volatility increases
Subscribe for More Information
10:43 EDTLHQuest Diagnostics jumps amid takeover speculation
The move higher in Quest Diagnostics (DGX), which was earlier halted for volatility and remains up 15% to $85 per share in morning trading, has been attributed to takeover speculation. Peer Lab Corp. (LH) is also up 3.9% to $125 in morning trading.
May 19, 2015
09:31 EDTLHORIG3N announces strategic collaboration with LabCorp
Subscribe for More Information
07:28 EDTLHUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
May 18, 2015
08:46 EDTLHLabCorp announces full portfolio of Hep C virus drug resistance assays
LabCorp announced the launch of two new Hepatitis C Virus drug resistance assays. The HCV NS5A and NS5B Drug Resistance Assays expand LabCorpís portfolio of HCV resistance tests that includes HCV GenoSure NS3/4A, which was launched in 2011. These tests are available through Monogram Biosciences, a member of the LabCorp Specialty Testing Group, and a leader in the development and commercialization of innovative antiviral diagnostics.
May 15, 2015
10:28 EDTMYGNMAC updates positive for NanoString, Myriad, Invitae, QIAGEN, says Leerink
Leerink said that coverage updates posted yesterday by Medicare Administrative Contractors were favorable for NanoString (NSTG), Myriad Genetics (MYGN), Invitae (NVTA) and QIAGEN (QGEN). The firm has Outperform ratings on NanoString and Invitae and Market Perform rating on the other two stocks listed.
07:09 EDTMYGNMyriad Genetics presents clinical data for Prolaris test
Myriad Genetics presented clinical data for its Prolaris test at the 2015 American Urological Association, or AUA, Annual Meeting being held May 15-19 in New Orleans, La. The results highlighted and underscored the significant ability of the Prolaris test to help physicians improve care for men diagnosed with prostate cancer. In this pioneering study, Myriad presented important new clinical validation data that establishes an active surveillance, or AS, threshold for men with localized prostate cancer. Specifically, the AS threshold is a composite of the Prolaris test score and clinicopathologic features. In the validation data featured at AUA, the pre-defined AS threshold was evaluated in 765 conservatively managed men, and the clinical endpoint was 10-year risk of prostate cancer mortality. The results showed that at the AS threshold, the predicted 10-year survival rate of prostate cancer patients was 97%. Conversely, there was a three percent risk of 10-year, prostate-specific mortality. Importantly, however, there were no observed prostate cancer-specific deaths over 10 years among men whose scores fell below the AS threshold. Additionally, a separate analysis of 4,218 patients was performed to determine what percentage of patients who were clinically tested with Prolaris would be candidates for active surveillance based on the validated AS threshold. Of this commercial cohort, 36% qualified for active surveillance based on their clinical features alone. However, when the Prolaris test was added to the clinical risk assessment, 60% of these patients fell below the AS threshold, representing a significant increase in the total number of candidates who may be eligible for active surveillance.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use